


Seviteronel

Chemical Properties

CAS No. :	1610537-15-9
Formula:	C ₁₈ H ₁₇ F ₄ N ₃ O ₃
Molecular Weight:	399.34
Storage:	Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i>



Biological Description

Description	Seviteronel (VT-464) is a novel CYP17 cleavage enzyme inhibitor and androgen receptor antagonist used in breast and prostate cancer research.
Targets(IC50)	Androgen Receptor,Cytochromes P450
In vitro	Seviteronel (VT-464) selectively inhibits CYP17 17,20-lyase to suppress androgen production without causing mineralocorticoid excess or cortisol depletion[2].
In vivo	Seviteronel(100 mg/kg bid; oral administration for 25 days) reduced tumor volume in castrated male mice with xenografts[2].

Solubility Information

Solubility	DMSO: 40 mg/mL (100.17 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.01 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5041 mL	12.5207 mL	25.0413 mL
5 mM	0.5008 mL	2.5041 mL	5.0083 mL
10 mM	0.2504 mL	1.2521 mL	2.5041 mL
50 mM	0.0501 mL	0.2504 mL	0.5008 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Rafferty SW, et al. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors. *Bioorg Med Chem Lett.* 2014 Jun 1;24(11):2444-7.

Sankar N. Maity, et al. Abstract 4772: Efficacy of VT-464, a novel selective inhibitor of cytochrome P450 17,20-lyase, in castrate-resistant prostate cancer models. *Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1*

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481